Bryn Mawr Capital Management LLC Has $5.81 Million Stake in Cencora, Inc. (NYSE:COR)

Bryn Mawr Capital Management LLC grew its position in Cencora, Inc. (NYSE:COR) by 335.4% during the fourth quarter, HoldingsChannel reports. The firm owned 25,863 shares of the company’s stock after buying an additional 19,923 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Cencora were worth $5,811,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. JFS Wealth Advisors LLC boosted its position in Cencora by 63.0% during the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company’s stock valued at $27,000 after acquiring an additional 46 shares during the last quarter. Concord Wealth Partners bought a new stake in shares of Cencora during the 3rd quarter valued at about $30,000. Householder Group Estate & Retirement Specialist LLC boosted its position in shares of Cencora by 85.2% during the 4th quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company’s stock valued at $33,000 after purchasing an additional 69 shares in the last quarter. Kentucky Trust Co acquired a new stake in Cencora during the fourth quarter worth approximately $33,000. Finally, WASHINGTON TRUST Co increased its holdings in Cencora by 37.7% in the fourth quarter. WASHINGTON TRUST Co now owns 168 shares of the company’s stock worth $38,000 after purchasing an additional 46 shares in the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Shares of NYSE COR opened at $245.37 on Thursday. The stock has a market cap of $47.58 billion, a price-to-earnings ratio of 34.90, a PEG ratio of 1.30 and a beta of 0.49. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The firm’s 50-day simple moving average is $239.11 and its 200 day simple moving average is $237.42.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Stockholders of record on Friday, February 14th will be issued a $0.55 dividend. The ex-dividend date of this dividend is Friday, February 14th. This represents a $2.20 annualized dividend and a dividend yield of 0.90%. Cencora’s dividend payout ratio is currently 31.29%.

Wall Street Analyst Weigh In

A number of research firms have issued reports on COR. UBS Group increased their price target on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Wells Fargo & Company increased their target price on shares of Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 29th. Evercore ISI lifted their price target on shares of Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Barclays increased their price objective on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, JPMorgan Chase & Co. boosted their target price on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Two research analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $277.90.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $243.97, for a total transaction of $12,198,500.00. Following the completion of the sale, the chairman now directly owns 326,557 shares of the company’s stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares in the company, valued at approximately $4,649,648.88. This represents a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.